115 results on '"Lindemans, Caroline"'
Search Results
2. Physical performance before and after hematopoietic stem cell transplantation in pediatric patients: a potential role for prehabilitation
- Author
-
den Hartog, Emma, Lindemans, Caroline A., Fiocco, Marta, Tissing, Wim J. E., and Verwaaijen, Emma J.
- Abstract
The trajectory of hematopoietic stem cell transplantation (HSCT) is often accompanied by physically disabling complications that impair physical performance of pediatric patients. However, knowledge about when impairments in physical performance arise and the factors contributing to these impairments is limited. Therefore, we conducted a retrospective analysis of physical performance 100 days post-HSCT in patients aged 3–18 years. Additionally, we aim to elucidate the relationship between pre- and post-HSCT physical performance and to unravel the impact of intensive HSCT procedures on post-HSCT physical performance. To explore associations between physical performance outcomes post-HSCT and covariates, linear regression models were estimated. Seventy-seven patients were included with a median age of 11.8 years (interquartile range: 5.9, 14.8). Patients had lower hip flexion muscle strength and appendicular skeletal muscle mass and a slower rising from the floor time 100 days post-HSCT compared to average values of the normal population. Pre-HSCT physical performance was positively associated with physical performance post-HSCT, independent of age, the cumulative glucocorticoids dosage administered and the total duration of hospitalization during the HSCT trajectory. This explorative study highlights the potential role of prehabilitation in enhancing physical performance of pediatric HSCT patients.
- Published
- 2024
- Full Text
- View/download PDF
3. Pathobiological signatures of dysbiotic lung injury in pediatric patients undergoing stem cell transplantation
- Author
-
Zinter, Matt S., Dvorak, Christopher C., Mayday, Madeline Y., Reyes, Gustavo, Simon, Miriam R., Pearce, Emma M., Kim, Hanna, Shaw, Peter J., Rowan, Courtney M., Auletta, Jeffrey J., Martin, Paul L., Godder, Kamar, Duncan, Christine N., Lalefar, Nahal R., Kreml, Erin M., Hume, Janet R., Abdel-Azim, Hisham, Hurley, Caitlin, Cuvelier, Geoffrey D. E., Keating, Amy K., Qayed, Muna, Killinger, James S., Fitzgerald, Julie C., Hanna, Rabi, Mahadeo, Kris M., Quigg, Troy C., Satwani, Prakash, Castillo, Paul, Gertz, Shira J., Moore, Theodore B., Hanisch, Benjamin, Abdel-Mageed, Aly, Phelan, Rachel, Davis, Dereck B., Hudspeth, Michelle P., Yanik, Greg A., Pulsipher, Michael A., Sulaiman, Imran, Segal, Leopoldo N., Versluys, Birgitta A., Lindemans, Caroline A., Boelens, Jaap J., and DeRisi, Joseph L.
- Abstract
Hematopoietic cell transplantation (HCT) uses cytotoxic chemotherapy and/or radiation followed by intravenous infusion of stem cells to cure malignancies, bone marrow failure and inborn errors of immunity, hemoglobin and metabolism. Lung injury is a known complication of the process, due in part to disruption in the pulmonary microenvironment by insults such as infection, alloreactive inflammation and cellular toxicity. How microorganisms, immunity and the respiratory epithelium interact to contribute to lung injury is uncertain, limiting the development of prevention and treatment strategies. Here we used 278 bronchoalveolar lavage (BAL) fluid samples to study the lung microenvironment in 229 pediatric patients who have undergone HCT treated at 32 children’s hospitals between 2014 and 2022. By leveraging paired microbiome and human gene expression data, we identified high-risk BAL compositions associated with in-hospital mortality (P= 0.007). Disadvantageous profiles included bacterial overgrowth with neutrophilic inflammation, microbiome contraction with epithelial fibroproliferation and profound commensal depletion with viral and staphylococcal enrichment, lymphocytic activation and cellular injury, and were replicated in an independent cohort from the Netherlands (P= 0.022). In addition, a broad array of previously occult pathogens was identified, as well as a strong link between antibiotic exposure, commensal bacterial depletion and enrichment of viruses and fungi. Together these lung–immune system–microorganism interactions clarify the important drivers of fatal lung injury in pediatric patients who have undergone HCT. Further investigation is needed to determine how personalized interpretation of heterogeneous pulmonary microenvironments may be used to improve pediatric HCT outcomes.
- Published
- 2024
- Full Text
- View/download PDF
4. Multicenter Long-Term Follow-Up of Allogeneic Hematopoietic Cell Transplantation with Omidubicel: A Pooled Analysis of Five Prospective Clinical Trials
- Author
-
Lin, Chenyu, Schwarzbach, Aurelie, Sanz, Jaime, Montesinos, Pau, Stiff, Patrick, Parikh, Suhag, Brunstein, Claudio, Cutler, Corey, Lindemans, Caroline A., Hanna, Rabi, Koh, Liang Piu, Jagasia, Madan H., Valcarcel, David, Maziarz, Richard T., Keating, Amy K., Hwang, William Y.K., Rezvani, Andrew R., Karras, Nicole A., Fernandes, Juliana F., Rocha, Vanderson, Badell, Isabel, Ram, Ron, Schiller, Gary J., Volodin, Leonid, Walters, Mark C., Hamerschlak, Nelson, Cilloni, Daniela, Frankfurt, Olga, McGuirk, Joseph P., Kurtzberg, Joanne, Sanz, Guillermo, Simantov, Ronit, and Horwitz, Mitchell E.
- Abstract
•Omidubicel is an ex vivo expanded stem cell product derived from umbilical cord blood (UCB).•We conducted a pooled analysis of long-term outcomes from 5 clinical trials evaluating omidubicel transplantation.•The 3-year overall survival and disease-free survival were 62.5% and 54.0%, respectively.•Durable long-term trilineage hematopoiesis and immune competence up to 8 years were noted.•One case of donor-derived myelodysplastic syndrome each was seen with omidubicel and standard UCB transplantation.
- Published
- 2023
- Full Text
- View/download PDF
5. Health-Related Quality of Life Following Allogeneic Hematopoietic Cell Transplantation with Omidubicel versus Umbilical Cord Blood
- Author
-
Lin, Chenyu, Sajeev, Gautam, Stiff, Patrick J., Brunstein, Claudio G., Cutler, Corey, Sanz, Guillermo, Lindemans, Caroline A., Rezvani, Andrew R., Hanna, Rabi, Koh, Liang Piu, Maziarz, Richard T., Hwang, William Y.K., Song, Yan, Liu, Qing, Manghani, Rocio, Sivaraman, Smitha, Signorovitch, James, Horwitz, Mitchell E., and Sung, Anthony D.
- Abstract
•Omidubicel significantly improved health-related quality of life (HRQL) in recipients of allogeneic hematopoietic cell transplantation.•Improvements in HRQL started at 42 days post-transplantation and persisted at 1 year.•Physical well-being returned to baseline at 6 months with omidubicel.•Shorter length of hospital stay was associated with higher HRQL scores.•Viral infections and graft-versus-host disease were associated with lower HRQL scores.
- Published
- 2023
- Full Text
- View/download PDF
6. International Recommendations for the Diagnosis and Management of Patients With Adrenoleukodystrophy
- Author
-
Engelen, Marc, van Ballegoij, Wouter J.C., Mallack, Eric James, Van Haren, Keith P., Köhler, Wolfgang, Salsano, Ettore, van Trotsenburg, A.S.P., Mochel, Fanny, Sevin, Caroline, Regelmann, Molly O., Tritos, Nicholas A., Halper, Alyssa, Lachmann, Robin H., Davison, James, Raymond, Gerald V., Lund, Troy C., Orchard, Paul J., Kuehl, Joern-Sven, Lindemans, Caroline A., Caruso, Paul, Turk, Bela Rui, Moser, Ann B., Vaz, Frédéric M., Ferdinandusse, Sacha, Kemp, Stephan, Fatemi, Ali, Eichler, Florian S., and Huffnagel, Irene C.
- Abstract
Pathogenic variants in the ABCD1gene cause adrenoleukodystrophy (ALD), a progressive metabolic disorder characterized by 3 core clinical syndromes: a slowly progressive myeloneuropathy, a rapidly progressive inflammatory leukodystrophy (cerebral ALD), and primary adrenal insufficiency. These syndromes are not present in all individuals and are not related to genotype. Cerebral ALD and adrenal insufficiency require early detection and intervention and warrant clinical surveillance because of variable penetrance and age at onset. Newborn screening has increased the number of presymptomatic individuals under observation, but clinical surveillance protocols vary. We used a consensus-based modified Delphi approach among 28 international ALD experts to develop best-practice recommendations for diagnosis, clinical surveillance, and treatment of patients with ALD. We identified 39 discrete areas of consensus. Regular monitoring to detect the onset of adrenal failure and conversion to cerebral ALD is recommended in all male patients. Hematopoietic cell transplant (HCT) is the treatment of choice for cerebral ALD. This guideline addresses a clinical need in the ALD community worldwide as the number of overall diagnoses and presymptomatic individuals is increasing because of newborn screening and greater availability of next-generation sequencing. The poor ability to predict the disease course informs current monitoring intervals but remains subject to change as more data emerge. This knowledge gap should direct future research and illustrates once again that international collaboration among physicians, researchers, and patients is essential to improving care.
- Published
- 2022
- Full Text
- View/download PDF
7. Hematopoietic stem cell transplantation for adolescents and adults with inborn errors of immunity: an EBMT IEWP study
- Author
-
Albert, Michael H., Sirait, Tiarlan, Eikema, Dirk-Jan, Bakunina, Katerina, Wehr, Claudia, Suarez, Felipe, Fox, Maria Laura, Mahlaoui, Nizar, Gennery, Andrew R., Lankester, Arjan C., Beier, Rita, Bernardo, Maria Ester, Bigley, Venetia, Lindemans, Caroline A., Burns, Siobhan O., Carpenter, Ben, Dybko, Jaroslaw, Güngör, Tayfun, Hauck, Fabian, Lum, Su Han, Balashov, Dmitry, Meisel, Roland, Moshous, Despina, Schulz, Ansgar, Speckmann, Carsten, Slatter, Mary A., Strahm, Brigitte, Uckan-Cetinkaya, Duygu, Meyts, Isabelle, Vallée, Tanja C., Wynn, Robert, Neven, Bénédicte, Morris, Emma C., Aiuti, Alessandro, Maschan, Alexei, Aljurf, Mahmoud, Gedde-Dahl, Tobias, Gurman, Gunhan, Bordon, Victoria, Kriván, Gergely, Locatelli, Franco, Porta, Fulvio, Valcárcel, David, Beguin, Yves, Faraci, Maura, Kröger, Nicolaus, Kulagin, Aleksandr, Shaw, Peter J., Veelken, Joan Hendrik, Diaz de Heredia, Cristina, Fagioli, Franca, Felber, Matthias, Gruhn, Bernd, Holter, Wolfgang, Rössig, Claudia, Sedlacek, Petr, Apperley, Jane, Ayas, Mouhab, Bodova, Ivana, Choi, Goda, Cornelissen, J.J., Sirvent, Anne, Khan, Anjum, Kupesiz, Alphan, Lenhoff, Stig, Ozdogu, Hakan, von der Weid, Nicolas, Rovira, Montserrat, Schots, Rik, and Vinh, Donald C.
- Abstract
Allogeneic hematopoietic stem cell transplantation (HSCT) is the gold standard curative therapy for infants and children with many inborn errors of immunity (IEI), but adolescents and adults with IEI are rarely referred for transplant. Lack of published HSCT outcome data outside small, single-center studies and perceived high risk of transplant-related mortality have delayed the adoption of HSCT for IEI patients presenting or developing significant organ damage later in life. This large retrospective, multicenter HSCT outcome study reports on 329 IEI patients (age range, 15-62.5 years at HSCT). Patients underwent first HSCT between 2000 and 2019. Primary endpoints were overall survival (OS) and event-free survival (EFS). We also evaluated the influence of IEI-subgroup and IEI-specific risk factors at HSCT, including infections, bronchiectasis, colitis, malignancy, inflammatory lung disease, splenectomy, hepatic dysfunction, and systemic immunosuppression. At a median follow-up of 44.3 months, the estimated OS at 1 and 5 years post-HSCT for all patients was 78% and 71%, and EFS was 65% and 62%, respectively, with low rates of severe acute (8%) or extensive chronic (7%) graft-versus-host disease. On univariate analysis, OS and EFS were inferior in patients with primary antibody deficiency, bronchiectasis, prior splenectomy, hepatic comorbidity, and higher hematopoietic cell transplant comorbidity index scores. On multivariable analysis, EFS was inferior in those with a higher number of IEI-associated complications. Neither age nor donor had a significant effect on OS or EFS. We have identified age-independent risk factors for adverse outcome, providing much needed evidence to identify which patients are most likely to benefit from HSCT.
- Published
- 2022
- Full Text
- View/download PDF
8. Mucormycosis in Children With Hematologic Malignancies: A Case Series and Review of the Literature
- Author
-
Loeffen, Yvette G. T., Scharloo, Fenna, Goemans, Bianca F., Heitink-Polle, Katja M. J., Lindemans, Caroline A., van der Bruggen, Tjomme, Hagen, Ferry, and Wolfs, Tom F. W.
- Published
- 2022
- Full Text
- View/download PDF
9. Clinical Features, Treatment, and Outcome of Pediatric Steroid Refractory Acute Graft-Versus-Host Disease: A Multicenter Study
- Author
-
Verbeek, Anne B., Jansen, Suze A., von Asmuth, Erik G.J., Lankester, Arjan C., Bresters, Dorine, Bierings, Marc, Mohseny, Alexander B., Lindemans, Caroline A., and Buddingh, Emilie P.
- Abstract
Steroid-refractory acute graft-versus-host disease (SR-aGvHD) is a severe complication in pediatric allogeneic hematopoietic stem cell transplantation (HSCT). We aimed to assess clinical course and outcomes of pediatric SR-aGvHD. We performed a retrospective nationwide multicenter cohort study in the Netherlands. All patients aged 0 to 18 years who underwent transplantation between 2010 and 2020 with SR-aGvHD were included. For each patient, weekly clinical aGvHD grade and stage, immunosuppressive treatment and clinical outcomes were collected. The primary study endpoint was the clinical course of SR-aGvHD over time. As a secondary outcome, factors influencing overall survival and SR-aGvHD remission were identified using a multistate Cox model. 20% of transplanted children developed grade II-IV aGvHD, of which 51% (n = 81) was SR-aGvHD. In these patients, second-line therapy was started at a median of 8 days after initial aGvHD-diagnosis. Forty-nine percent of SR-aGvHD patients received 3 or more lines of therapy. One year after start of second-line therapy, 34 patients (42%) were alive and in remission of aGvHD, 14 patients (17%) had persistent GvHD, and 33 patients (41%) had died. SR-aGvHD remission rate was lower in cord blood graft recipients than in bone marrow (BM) or peripheral blood stem cell (PBSC) recipients (hazard ratio [HR] = 0.51, 0.27-0.94, P = .031). Older age was associated with higher mortality (HR = 2.62, 1.04-6.60, P = .04, fourth quartile [aged 13.9-17.9] versus first quartile [aged 0.175-3.01]). In BM/PBSC recipients older age was also associated with lower remission rates (HR = 0.9, 0.83-0.96, P = .004). Underlying diagnosis, donor matching or choice of second-line therapy were not associated with outcome. Respiratory insufficiency caused by pulmonary GvHD was a prominent cause of death (26% of deceased). Our study demonstrates that SR-aGvHD confers a high mortality risk in pediatric HSCT. Older age and use of CB grafts are associated with an unfavorable outcome. Multicenter studies investigating novel treatment strategies to prevent pediatric SR-aGvHD and inclusion of children in ongoing trials, together with timely initiation of second-line interventions are pivotal to further reduce GvHD-related mortality.
- Published
- 2022
- Full Text
- View/download PDF
10. Outcomes after Hematopoietic Cell Transplantation for Hurler Syndrome after Implementation Newborn Screening in US and Europe
- Author
-
Boelens, Jaap-Jan, Lindemans, Caroline A., van Hasselt, Peter, Koop, Klaas, Cancio, Maria I., Orchard, Paul J., and Lund, Troy C.
- Abstract
Hurler syndrome (HS), the most severe phenotype in the spectrum of Mucopolysaccharidosis type I, is caused by a severe deficiency of the lysosomal enzyme alpha-L-iduronidase (IDUA). HS is clinically characterized by a progressive and ultimately fatal multi-system deterioration with involvement of the central nervous system. At present, hematopoietic cell transplantation (HCT) is the only treatment able to prevent central nervous system deterioration and therefore considered the treatment of choice in HS. In large intercontinental cohorts, predictors for outcomes (short and long-term) were found to be age at HCT and enzyme levels after HCT. Newborn screening (NBS) and early HCT could therefore potentially impact outcomes. In several States in the US and Europe NBS has been implemented over the last couple years. We were interested in the age at HCT and outcome of HS patients diagnosed by NBS.
- Published
- 2024
- Full Text
- View/download PDF
11. Design of a Multi-Center Randomized Active Controlled Phase 3 Clinical Trial (HURCULES) Evaluating the Safety and Efficacy of OTL-203 in Patients with MPS-IH Versus Standard of Care with Allogeneic Hematopoietic Stem Cell Transplantation
- Author
-
Gupta, Ashish O., Wynn, Robert F, Kharbanda, Sandhya, Lindemans, Caroline A., Ahrens-Nicklas, Rebecca, van Hasselt, Peter M., Lund, Troy C., Olson, Timothy S., Tucci, Francesca, Martin, Leonie, Boeglin, Nathalie, Brooks, Jean, Syonmez, Su, Campbell, Laura, Harmatz, Paul, Jones, Simon A., Orchard, Paul J., and Bernardo, Maria Ester
- Abstract
Mucopolysaccharidosis type I Hurler (MPS-IH) is an autosomal recessive lysosomal storage disorder characterized by deficiency of alpha-L-iduronidase (IDUA), which is responsible for the degradation of glycosaminoglycans (GAGs). The accumulation of GAGs throughout the body and brain results in multi-organ dysfunction causing a wide range of musculoskeletal, cardiopulmonary, ophthalmic and auditory abnormalities, progressive neurologic disease, and early death.
- Published
- 2024
- Full Text
- View/download PDF
12. Evaluation of Mobilization, Apheresis, and Conditioning Regimen and Engraftment in Patients Receiving One-Time Gene Therapy with Elivaldogene Autotemcel (Eli-cel) for Cerebral Adrenoleukodystrophy (CALD)
- Author
-
Duncan, Christine N., Orchard, Paul J., Eichler, Florian S., Kühl, Jörn-Sven, De Oliveira, Satiro N., Thrasher, Adrian J., Chiesa, Robert, Dalle, Jean-Hugues, Shah, Ami J., Locatelli, Franco, Smith, Nicholas J.C., Fernandes, Juliana Folloni, Amartino, Hernán M., Lindemans, Caroline A., Zhao, Jack, Singh, Ajay, Thakar, Himal L., Prasad, Vinod K., Dietz, Andrew C., and Williams, David A.
- Abstract
Eli-cel, an autologous hematopoietic stem cell (HSC) gene therapy consisting of CD34+ cells transduced with ABCD1cDNA using a Lenti-D lentiviral vector (LVV), is approved for the treatment of CALD.
- Published
- 2024
- Full Text
- View/download PDF
13. Real World Use of the Pediatric Disease Risk Index for Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia: A Multicenter Study
- Author
-
Lucas, Alexandre G. Troullioud, Bhoopalan, Senthil Velan, Nierkens, Stefan, de Koning, Coco, Keerthi, Dinesh, Seetharaman, Aditya, Naik, Swati, Prockop, Susan E., Sharma, Akshay, Boelens, Jaap Jan, and Lindemans, Caroline A.
- Abstract
To determine the risk of relapse of hematologic malignancies after allogeneic hematopoietic cell transplantation (allo-HCT), a disease risk index (DRI) tool has been used extensively for adult patients. In 2021 a validated DRI, considering age and disease status, for pediatric patients was developed by Qayed et al. (Blood, 2021, 137[7]).
- Published
- 2024
- Full Text
- View/download PDF
14. Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia
- Author
-
Dekker, Linde, Calkoen, Friso G., Jiang, Yilin, Blok, Hilly, Veldkamp, Saskia R., De Koning, Coco, Spoon, Maike, Admiraal, Rick, Hoogerbrugge, Peter, Vormoor, Britta, Vormoor, H. Josef, Visscher, Henk, Bierings, Marc, Van Der Vlugt, Marieke, Van Tinteren, Harm, Nijstad, A. Laura, Huitema, Alwin D. R., Van Der Elst, Kim C. M., Pieters, Rob, Lindemans, Caroline A., and Nierkens, Stefan
- Abstract
The addition of fludarabine to cyclophosphamide as a lymphodepleting regimen prior to CD19 chimeric antigen receptor (CAR) T-cell therapy significantly improved outcomes in patients with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL). Fludarabine exposure, previously shown to be highly variable when dosing is based on body surface area (BSA), is a predictor for survival in allogeneic hematopoietic cell transplantation (allo-HCT). Hence, we hypothesized that an optimal exposure of fludarabine might be of clinical importance in CD19 CAR T-cell treatment. We examined the effect of cumulative fludarabine exposure during lymphodepletion, defined as concentration-time curve (AUC), on clinical outcome and lymphocyte kinetics. A retrospective analysis was conducted with data from 26 patients receiving tisagenlecleucel for r/r B-ALL. Exposure of fludarabine was shown to be a predictor for leukemia-free survival (LFS), B-cell aplasia, and CD19-positive relapse following CAR T-cell infusion. Minimal event probability was observed at a cumulative fludarabine AUCT0−∞ ≥14 mg*h/L, and underexposure was defined as an AUCT0−∞ <14 mg*h/L. In the underexposed group, the median LFS was 1.8 months, and the occurrence of CD19-positive relapse within 1 year was 100%, which was higher compared with the group with an AUCT0−∞ ≥14 mg*h/L (12.9 months; P < .001; and 27.4%; P = .0001, respectively). Furthermore, the duration of B-cell aplasia within 6 months was shorter in the underexposed group (77.3% vs 37.3%; P = .009). These results suggest that optimizing fludarabine exposure may have a relevant impact on LFS following CAR T-cell therapy, which needs to be validated in a prospective clinical trial.
- Published
- 2022
- Full Text
- View/download PDF
15. Challenges and opportunities targeting mechanisms of epithelial injury and recovery in acute intestinal graft-versus-host disease
- Author
-
Jansen, Suze A., Nieuwenhuis, Edward E.S., Hanash, Alan M., and Lindemans, Caroline A.
- Abstract
Despite advances in immunosuppressive prophylaxis and overall supportive care, gastrointestinal (GI) graft-versus-host disease (GVHD) remains a major, lethal side effect after allogeneic hematopoietic stem cell transplantation (allo-HSCT). It has become increasingly clear that the intestinal epithelium, in addition to being a target of transplant-related toxicity and GVHD, plays an important role in the onset of GVHD. Over the last two decades, increased understanding of the epithelial constituents and their microenvironment has led to the development of novel prophylactic and therapeutic interventions, with the potential to protect the intestinal epithelium from GVHD-associated damage and promote its recovery following insult. In this review, we will discuss intestinal epithelial injury and the role of the intestinal epithelium in GVHD pathogenesis. In addition, we will highlight possible approaches to protect the GI tract from damage posttransplant and to stimulate epithelial regeneration, in order to promote intestinal recovery. Combined treatment modalities integrating immunomodulation, epithelial protection, and induction of regeneration may hold the key to unlocking mucosal recovery and optimizing therapy for acute intestinal GVHD.
- Published
- 2022
- Full Text
- View/download PDF
16. Outcome of haematopoietic cell transplantation in children with lysosomal acid lipase deficiency: a study on behalf of the EBMT Inborn Errors Working Party
- Author
-
Lum, Su Han, Minkov, Milen, Jones, Simon A., Hazelaar, Sheree, Sirait, Tiarlan, Potter, Jane E., Stepensky, Polina, Garban, Frederic, Pichler, Herbert, Stein, Jerry, Kaya, Zuhre, Schulz, Ansgar, Mellgren, Karin, Diaz de Heredia, Cristina, Pochon, Cecile, Riesco, Susana, Diaz, Miguel Angel, Michel, Gérard, Lindemans, Caroline, Gruhn, Bernd, Albert, Michael H., Lankester, Arjan C., Neven, Bénédicte, and Wynn, Robert
- Published
- 2023
- Full Text
- View/download PDF
17. Hematopoietic stem cell transplantation for Wiskott-Aldrich syndrome: an EBMT Inborn Errors Working Party analysis
- Author
-
Albert, Michael H., Slatter, Mary A., Gennery, Andrew R., Güngör, Tayfun, Bakunina, Katerina, Markovitch, Benyamin, Hazelaar, Sheree, Sirait, Tiarlan, Courteille, Virginie, Aiuti, Alessandro, Aleinikova, Olga V., Balashov, Dmitry, Bernardo, Maria Ester, Bodova, Ivana, Bruno, Benedicte, Cavazzana, Marina, Chiesa, Robert, Fischer, Alain, Hauck, Fabian, Ifversen, Marianne, Kałwak, Krzysztof, Klein, Christoph, Kulagin, Alexander, Kupesiz, Alphan, Kuskonmaz, Baris, Lindemans, Caroline A., Locatelli, Franco, Lum, Su Han, Maschan, Alexey, Meisel, Roland, Moshous, Despina, Porta, Fulvio, Sauer, Martin G., Sedlacek, Petr, Schulz, Ansgar, Suarez, Felipe, Vallée, Tanja C., Winiarski, Jacek H., Zecca, Marco, Neven, Bénédicte, Veys, Paul, and Lankester, Arjan C.
- Abstract
Allogeneic hematopoietic stem cell transplantation (HSCT) is a potentially curative treatment for patients affected by Wiskott-Aldrich syndrome (WAS). Reported HSCT outcomes have improved over time with respect to overall survival, but some studies have identified older age and HSCT from alternative donors as risk factors predicting poorer outcome. We analyzed 197 patients undergoing transplant at European Society for Blood and Marrow Transplantation centers between 2006 and 2017 who received conditioning as recommended by the Inborn Errors Working Party (IEWP): either busulfan (n = 103) or treosulfan (n = 94) combined with fludarabine ± thiotepa. After a median follow-up post-HSCT of 44.9 months, 176 patients were alive, resulting in a 3-year overall survival of 88.7% and chronic graft-versus-host disease (GVHD)-free survival (events include death, graft failure, and severe chronic GVHD) of 81.7%. Overall survival and chronic GVHD-free survival were not significantly affected by conditioning regimen (busulfan- vs treosulfan-based), donor type (matched sibling donor/matched family donor vs matched unrelated donor/mismatched unrelated donor vs mismatched family donor), or period of HSCT (2006-2013 vs 2014-2017). Patients aged <5 years at HSCT had a significantly better overall survival. The overall cumulative incidences of grade III to IV acute GVHD and extensive/moderate/severe chronic GVHD were 6.6% and 2.1%, respectively. Patients receiving treosulfan-based conditioning had a higher incidence of graft failure and mixed donor chimerism and more frequently underwent secondary procedures (second HSCT, unconditioned stem cell boost, donor lymphocyte infusion, or splenectomy). In summary, HSCT for WAS with conditioning regimens currently recommended by IEWP results in excellent survival and low rates of GVHD, regardless of donor or stem cell source, but age ≥5 years remains a risk factor for overall survival.
- Published
- 2022
- Full Text
- View/download PDF
18. Hematopoietic stem cell transplantation for Wiskott-Aldrich syndrome: an EBMT Inborn Errors Working Party analysis
- Author
-
Albert, Michael H., Slatter, Mary A., Gennery, Andrew R., Güngör, Tayfun, Bakunina, Katerina, Markovitch, Benyamin, Hazelaar, Sheree, Sirait, Tiarlan, Courteille, Virginie, Aiuti, Alessandro, Aleinikova, Olga V., Balashov, Dmitry, Bernardo, Maria Ester, Bodova, Ivana, Bruno, Benedicte, Cavazzana, Marina, Chiesa, Robert, Fischer, Alain, Hauck, Fabian, Ifversen, Marianne, Kałwak, Krzysztof, Klein, Christoph, Kulagin, Alexander, Kupesiz, Alphan, Kuskonmaz, Baris, Lindemans, Caroline A., Locatelli, Franco, Lum, Su Han, Maschan, Alexey, Meisel, Roland, Moshous, Despina, Porta, Fulvio, Sauer, Martin G., Sedlacek, Petr, Schulz, Ansgar, Suarez, Felipe, Vallée, Tanja C., Winiarski, Jacek H., Zecca, Marco, Neven, Bénédicte, Veys, Paul, and Lankester, Arjan C.
- Abstract
Allogeneic hematopoietic stem cell transplantation (HSCT) is a potentially curative treatment for patients affected by Wiskott-Aldrich syndrome (WAS). Reported HSCT outcomes have improved over time with respect to overall survival, but some studies have identified older age and HSCT from alternative donors as risk factors predicting poorer outcome. We analyzed 197 patients undergoing transplant at European Society for Blood and Marrow Transplantation centers between 2006 and 2017 who received conditioning as recommended by the Inborn Errors Working Party (IEWP): either busulfan (n = 103) or treosulfan (n = 94) combined with fludarabine ± thiotepa. After a median follow-up post-HSCT of 44.9 months, 176 patients were alive, resulting in a 3-year overall survival of 88.7% and chronic graft-versus-host disease (GVHD)-free survival (events include death, graft failure, and severe chronic GVHD) of 81.7%. Overall survival and chronic GVHD-free survival were not significantly affected by conditioning regimen (busulfan- vs treosulfan-based), donor type (matched sibling donor/matched family donor vs matched unrelated donor/mismatched unrelated donor vs mismatched family donor), or period of HSCT (2006-2013 vs 2014-2017). Patients aged <5 years at HSCT had a significantly better overall survival. The overall cumulative incidences of grade III to IV acute GVHD and extensive/moderate/severe chronic GVHD were 6.6% and 2.1%, respectively. Patients receiving treosulfan-based conditioning had a higher incidence of graft failure and mixed donor chimerism and more frequently underwent secondary procedures (second HSCT, unconditioned stem cell boost, donor lymphocyte infusion, or splenectomy). In summary, HSCT for WAS with conditioning regimens currently recommended by IEWP results in excellent survival and low rates of GVHD, regardless of donor or stem cell source, but age ≥5 years remains a risk factor for overall survival.
- Published
- 2022
- Full Text
- View/download PDF
19. Clofarabine-fludarabine-busulfan in HCT for pediatric leukemia: an effective, low toxicity, TBI-free conditioning regimen
- Author
-
Versluijs, A. Birgitta, de Koning, Coco C. H., Lankester, Arjan C., Nierkens, Stefan, Kollen, Wouter J., Bresters, Dorine, Lindemans, Caroline A., Boelens, Jaap Jan, and Bierings, Marc
- Abstract
We prospectively studied clofarabine-fludarabine-busulfan (CloFluBu)-conditioning in allogeneic hematopoietic cell therapy (HCT) for lymphoid and myeloid malignancies and hypothesized that CloFluBu provides a less toxic alternative to conventional conditioning regimens, with adequate antileukemic activity. All patients receiving their first HCT, from 2011-2019, were included and received CloFluBu. The primary endpoint was event-free survival (EFS). Secondary endpoints were overall survival (OS), graft-versus-host disease (GvHD)-relapse-free survival (GRFS), treatment-related mortality (TRM), cumulative incidence of relapse (CIR), acute and chronic GvHD (aGvHD and cGvHD), and veno-occlusive disease (VOD). Cox proportional hazard and Fine and Gray competing-risk models were used for data analysis. One hundred fifty-five children were included: 60 acute lymphoid leukemia (ALL), 69 acute myeloid leukemia (AML), and 26 other malignancies (mostly MDS-EB). The median age was 9.7 (0.5 to 18.6) years. Estimated 2-year EFS was 72.0% ± 6.0 in ALL patients, and 62.4% ± 6.0 in AML patients. TRM in the whole cohort was 11.0% ± 2.6, incidence of aGvHD 3 to 4 at 6 months was 12.3% ± 2.7, extensive cGvHD at 2 years was 6.4% ± 2.1. Minimal residual disease-positivity prior to HCT was associated with higher CIR, both in ALL and AML. CloFluBu showed limited toxicity and encouraging EFS. CloFluBu is a potentially less toxic alternative to conventional conditioning regimens. Randomized prospective studies are needed.
- Published
- 2022
- Full Text
- View/download PDF
20. Clofarabine-fludarabine-busulfan in HCT for pediatric leukemia: an effective, low toxicity, TBI-free conditioning regimen
- Author
-
Versluijs, A. Birgitta, de Koning, Coco C.H., Lankester, Arjan C., Nierkens, Stefan, Kollen, Wouter J., Bresters, Dorine, Lindemans, Caroline A., Boelens, Jaap Jan, and Bierings, Marc
- Abstract
We prospectively studied clofarabine-fludarabine-busulfan (CloFluBu)-conditioning in allogeneic hematopoietic cell therapy (HCT) for lymphoid and myeloid malignancies and hypothesized that CloFluBu provides a less toxic alternative to conventional conditioning regimens, with adequate antileukemic activity. All patients receiving their first HCT, from 2011-2019, were included and received CloFluBu. The primary endpoint was event-free survival (EFS). Secondary endpoints were overall survival (OS), graft-versus-host disease (GvHD)-relapse-free survival (GRFS), treatment-related mortality (TRM), cumulative incidence of relapse (CIR), acute and chronic GvHD (aGvHD and cGvHD), and veno-occlusive disease (VOD). Cox proportional hazard and Fine and Gray competing-risk models were used for data analysis. One hundred fifty-five children were included: 60 acute lymphoid leukemia (ALL), 69 acute myeloid leukemia (AML), and 26 other malignancies (mostly MDS-EB). The median age was 9.7 (0.5 to 18.6) years. Estimated 2-year EFS was 72.0% ± 6.0 in ALL patients, and 62.4% ± 6.0 in AML patients. TRM in the whole cohort was 11.0% ± 2.6, incidence of aGvHD 3 to 4 at 6 months was 12.3% ± 2.7, extensive cGvHD at 2 years was 6.4% ± 2.1. Minimal residual disease-positivity prior to HCT was associated with higher CIR, both in ALL and AML. CloFluBu showed limited toxicity and encouraging EFS. CloFluBu is a potentially less toxic alternative to conventional conditioning regimens. Randomized prospective studies are needed.
- Published
- 2022
- Full Text
- View/download PDF
21. Variables affecting outcomes after allogeneic hematopoietic stem cell transplant for cerebral adrenoleukodystrophy
- Author
-
Chiesa, Robert, Boelens, Jaap Jan, Duncan, Christine N., Kühl, Jörn-Sven, Sevin, Caroline, Kapoor, Neena, Prasad, Vinod K., Lindemans, Caroline A., Jones, Simon A., Amartino, Hernan M., Algeri, Mattia, Bunin, Nancy, Diaz-de-Heredia, Cristina, Loes, Daniel J., Shamir, Esther, Timm, Alison, McNeil, Elizabeth, Dietz, Andrew C., and Orchard, Paul J.
- Abstract
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) in early cerebral adrenoleukodystrophy can stabilize neurologic function and improve survival but has associated risks including transplant-related mortality (TRM), graft failure, and graft-versus-host disease (GVHD). An observational study of 59 patients with median age at allo-HSCT of 8 years addressed impact of donor source, donor match, conditioning regimen, and cerebral disease stage on first allo-HSCT outcomes. Efficacy analyses included 53 patients stratified by disease category: advanced disease (AD; n = 16) with Loes score >9 or neurological function score (NFS) >1 and 2 early disease (ED) cohorts (ED1 [Loes ≤4 and NFS ≤1; n = 24] and ED2 [Loes >4-9 and NFS ≤1; n = 13]). Survival free of major functional disabilities and without second allo-HSCT at 4 years was significantly higher in the ED (66%) vs AD (41%) cohort (P = .015) and comparable between ED1 and ED2 cohorts (P = .991). The stabilization of neurologic function posttransplant was greater in the ED vs AD cohort, with a median change from baseline at 24 months after allo-HSCT in NFS and Loes score, respectively, of 0 and 0.5 in ED1 (n = 13), 0.5 and 0 in ED2 (n = 6), and 2.5 and 3.0 (n = 4) in AD cohort. TRM was lower in the ED (7%) compared with the AD (22%) cohort; however, the difference was not significant (P = .094). Transplant-related safety outcomes were also affected by transplant-related characteristics: graft failure incidence was significantly higher with unrelated umbilical cord grafts vs matched related donors (P = .039), and acute GVHD and graft failure incidences varied by conditioning regimen. This study was registered at www://clinicaltrials.gov as #NCT02204904.
- Published
- 2022
- Full Text
- View/download PDF
22. Variables affecting outcomes after allogeneic hematopoietic stem cell transplant for cerebral adrenoleukodystrophy
- Author
-
Chiesa, Robert, Boelens, Jaap Jan, Duncan, Christine N., Kühl, Jörn-Sven, Sevin, Caroline, Kapoor, Neena, Prasad, Vinod K., Lindemans, Caroline A., Jones, Simon A., Amartino, Hernan M., Algeri, Mattia, Bunin, Nancy, Diaz-de-Heredia, Cristina, Loes, Daniel J., Shamir, Esther, Timm, Alison, McNeil, Elizabeth, Dietz, Andrew C., and Orchard, Paul J.
- Abstract
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) in early cerebral adrenoleukodystrophy can stabilize neurologic function and improve survival but has associated risks including transplant-related mortality (TRM), graft failure, and graft-versus-host disease (GVHD). An observational study of 59 patients with median age at allo-HSCT of 8 years addressed impact of donor source, donor match, conditioning regimen, and cerebral disease stage on first allo-HSCT outcomes. Efficacy analyses included 53 patients stratified by disease category: advanced disease (AD; n = 16) with Loes score >9 or neurological function score (NFS) >1 and 2 early disease (ED) cohorts (ED1 [Loes ≤4 and NFS ≤1; n = 24] and ED2 [Loes >4-9 and NFS ≤1; n = 13]). Survival free of major functional disabilities and without second allo-HSCT at 4 years was significantly higher in the ED (66%) vs AD (41%) cohort (P= .015) and comparable between ED1 and ED2 cohorts (P= .991). The stabilization of neurologic function posttransplant was greater in the ED vs AD cohort, with a median change from baseline at 24 months after allo-HSCT in NFS and Loes score, respectively, of 0 and 0.5 in ED1 (n = 13), 0.5 and 0 in ED2 (n = 6), and 2.5 and 3.0 (n = 4) in AD cohort. TRM was lower in the ED (7%) compared with the AD (22%) cohort; however, the difference was not significant (P= .094). Transplant-related safety outcomes were also affected by transplant-related characteristics: graft failure incidence was significantly higher with unrelated umbilical cord grafts vs matched related donors (P= .039), and acute GVHD and graft failure incidences varied by conditioning regimen. This study was registered at www://clinicaltrials.govas #NCT02204904.
- Published
- 2022
- Full Text
- View/download PDF
23. Individualised dosing of anti-thymocyte globulin in paediatric unrelated allogeneic haematopoietic stem-cell transplantation (PARACHUTE): a single-arm, phase 2 clinical trial
- Author
-
Admiraal, Rick, Nierkens, Stefan, Bierings, Marc B, Bredius, Robbert G M, van Vliet, Ineke, Jiang, Yilin, Lopez-Yurda, Marta, Versluijs, A Birgitta, Zwaan, C Michel, Lindemans, Caroline A, and Boelens, Jaap Jan
- Abstract
Anti-thymocyte globulin, which is used in the conditioning of haematopoietic stem-cell transplantation (HSCT) to prevent graft-versus-host disease (GVHD) and graft failure, has highly variable pharmacokinetics. Overexposure to anti-thymocyte globulin leads to poor CD4+T-cell immune reconstitution, which is associated with inferior overall survival. We hypothesised that individualised anti-thymocyte globulin dosing would promote CD4+immune reconstitution, while still preventing GVHD and graft failure.
- Published
- 2022
- Full Text
- View/download PDF
24. Challenges and opportunities targeting mechanisms of epithelial injury and recovery in acute intestinal graft-versus-host disease
- Author
-
Jansen, Suze A., Nieuwenhuis, Edward E. S., Hanash, Alan M., and Lindemans, Caroline A.
- Abstract
Despite advances in immunosuppressive prophylaxis and overall supportive care, gastrointestinal (GI) graft-versus-host disease (GVHD) remains a major, lethal side effect after allogeneic hematopoietic stem cell transplantation (allo-HSCT). It has become increasingly clear that the intestinal epithelium, in addition to being a target of transplant-related toxicity and GVHD, plays an important role in the onset of GVHD. Over the last two decades, increased understanding of the epithelial constituents and their microenvironment has led to the development of novel prophylactic and therapeutic interventions, with the potential to protect the intestinal epithelium from GVHD-associated damage and promote its recovery following insult. In this review, we will discuss intestinal epithelial injury and the role of the intestinal epithelium in GVHD pathogenesis. In addition, we will highlight possible approaches to protect the GI tract from damage posttransplant and to stimulate epithelial regeneration, in order to promote intestinal recovery. Combined treatment modalities integrating immunomodulation, epithelial protection, and induction of regeneration may hold the key to unlocking mucosal recovery and optimizing therapy for acute intestinal GVHD.
- Published
- 2022
- Full Text
- View/download PDF
25. Lymphoid and myeloid immune cell reconstitution after nicotinamide-expanded cord blood transplantation
- Author
-
de Koning, Coco, Tao, Weiyang, Lacna, Amelia, van Veghel, Karin, Horwitz, Mitchell E., Sanz, Guillermo, Jagasia, Madan H., Wagner, John E., Stiff, Patrick J., Hanna, Rabi, Cilloni, Daniela, Valcárcel, David, Peled, Tony, Galamidi Cohen, Einat, Goshen, Uri, Pandit, Aridaman, Lindemans, Caroline A., Jan Boelens, Jaap, and Nierkens, Stefan
- Abstract
Omidubicel (nicotinamide-expanded cord blood) is a potential alternative source for allogeneic hematopoietic cell transplantation (HCT) when an HLA-identical donor is lacking. A phase I/II trial with standalone omidubicel HCT showed rapid and robust neutrophil and platelet engraftment. In this study, we evaluated the immune reconstitution (IR) of patients receiving omidubicel grafts during the first 6 months post-transplant, as IR is critical for favorable outcomes of the procedure. Data was collected from the omidubicel phase I-II international, multicenter trial. The primary endpoint was the probability of achieving adequate CD4+ T-cell IR (CD4IR: > 50 × 106/L within 100 days). Secondary endpoints were the recovery of T-cells, natural killer (NK)-cells, B-cells, dendritic cells (DC), and monocytes as determined with multicolor flow cytometry. LOESS-regression curves and cumulative incidence plots were used for data description. Thirty-six omidubicel recipients (median 44; 13–63 years) were included, and IR data was available from 28 recipients. Of these patients, 90% achieved adequate CD4IR. Overall, IR was complete and consisted of T-cell, monocyte, DC, and notably fast NK- and B-cell reconstitution, compared to conventional grafts. Our data show that transplantation of adolescent and adult patients with omidubicel results in full and broad IR, which is comparable with IR after HCT with conventional graft sources.
- Published
- 2021
- Full Text
- View/download PDF
26. Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study
- Author
-
Horwitz, Mitchell E., Stiff, Patrick J., Cutler, Corey, Brunstein, Claudio, Hanna, Rabi, Maziarz, Richard T., Rezvani, Andrew R., Karris, Nicole A., McGuirk, Joseph, Valcarcel, David, Schiller, Gary J., Lindemans, Caroline A., Hwang, William Y. K., Koh, Liang Piu, Keating, Amy, Khaled, Yasser, Hamerschlak, Nelson, Frankfurt, Olga, Peled, Tony, Segalovich, Irit, Blackwell, Beth, Wease, Stephen, Freedman, Laurence S., Galamidi-Cohen, Einat, and Sanz, Guillermo
- Abstract
Omidubicel is an ex vivo expanded hematopoietic progenitor cell and nonexpanded myeloid and lymphoid cell product derived from a single umbilical cord blood unit. We report results of a phase 3 trial to evaluate the efficacy of omidubicel compared with standard umbilical cord blood transplantation (UCBT). Between January 2017 and January 2020, 125 patients age 13 to 65 years with hematologic malignancies were randomly assigned to omidubicel vs standard UCBT. Patients received myeloablative conditioning and prophylaxis with a calcineurin inhibitor and mycophenolate mofetil for graft-versus-host disease (GVHD). The primary end point was time to neutrophil engraftment. The treatment arms were well balanced and racially diverse. Median time to neutrophil engraftment was 12 days (95% confidence interval [CI], 10-14 days) for the omidubicel arm and 22 days (95% CI, 19-25 days) for the control arm (P < .001). The cumulative incidence of neutrophil engraftment was 96% for patients receiving omidubicel and 89% for patients receiving control transplants. The omidubicel arm had faster platelet recovery (55% vs 35% recovery by 42 days; P = .028), had a lower incidence of first grade 2 to 3 bacterial or invasive fungal infection (37% vs 57%; P = .027), and spent more time out of hospital during the first 100 days after transplant (median, 61 vs 48 days; P = .005) than controls. Differences in GVHD and survival between the 2 arms were not statistically significant. Transplantation with omidubicel results in faster hematopoietic recovery and reduces early transplant-related complications compared with standard UCBT. The results suggest that omidubicel may be considered as a new standard of care for adult patients eligible for UCBT. The trial was registered at www.clinicaltrials.gov as #NCT02730299.
- Published
- 2021
- Full Text
- View/download PDF
27. Long-term effect of hematopoietic cell transplantation on systemic inflammation in patients with mucopolysaccharidoses
- Author
-
van den Broek, Brigitte T.A., Lindemans, Caroline A., Boelens, Jaap Jan, Delemarre, Eveline M., Drylewicz, Julia, Verhoeven-Duif, Nanda, van Hasselt, Peter M., and Nierkens, Stefan
- Abstract
Mucopolysaccharidoses (MPS) are devastating inherited diseases treated with hematopoietic cell transplantation (HCT). However, disease progression, especially skeletal, still occurs in all patients. Secondary inflammation has been hypothesized to be a cause. To investigate whether systemic inflammation is present in untreated patients and to evaluate the effect of HCT on systemic inflammation, dried blood spots (n = 66) of patients with MPS (n = 33) treated with HCT between 2003 and 2019 were included. Time points consisted of pre-HCT and, for patients with MPS type I (MPS I), also at 1, 3, and 10 years of follow-up. Ninety-two markers of the OLINK inflammation panel were measured and compared with those of age-matched control subjects (n = 31) by using principal component analysis and Wilcoxon rank sum tests with correction. Median age at transplantation was 1.3 years (range, 0.2-4.8 years), and median time of pre-HCT sample to transplantation was 0.1 year. Normal leukocyte enzyme activity levels were achieved in 93% of patients post-HCT. Pretransplant samples showed clear separation of patients and control subjects. Markers that differentiated pre-HCT between control subjects and patients were mainly pro-inflammatory (50%) or related to bone homeostasis and extracellular matrix degradation (33%). After 10 years' follow-up, only 5 markers (receptor activator of nuclear factor kappa-Β ligand, osteoprotegerin, axis inhibition protein 1 [AXIN1], stem cell factor, and Fms-related tyrosine kinase 3 ligand) remained significantly increased, with a large fold change difference between patients with MPS I and control subjects. In conclusion, systemic inflammation is present in untreated MPS patients and is reduced upon treatment with HCT. Markers related to bone homeostasis remain elevated up to 10 years after HCT and possibly reflect the ongoing skeletal disease, making them potential biomarkers for the evaluation of new therapies.
- Published
- 2021
- Full Text
- View/download PDF
28. Long-term effect of hematopoietic cell transplantation on systemic inflammation in patients with mucopolysaccharidoses
- Author
-
van den Broek, Brigitte T.A., Lindemans, Caroline A., Boelens, Jaap Jan, Delemarre, Eveline M., Drylewicz, Julia, Verhoeven-Duif, Nanda, van Hasselt, Peter M., and Nierkens, Stefan
- Abstract
Mucopolysaccharidoses (MPS) are devastating inherited diseases treated with hematopoietic cell transplantation (HCT). However, disease progression, especially skeletal, still occurs in all patients. Secondary inflammation has been hypothesized to be a cause. To investigate whether systemic inflammation is present in untreated patients and to evaluate the effect of HCT on systemic inflammation, dried blood spots (n = 66) of patients with MPS (n = 33) treated with HCT between 2003 and 2019 were included. Time points consisted of pre-HCT and, for patients with MPS type I (MPS I), also at 1, 3, and 10 years of follow-up. Ninety-two markers of the OLINK inflammation panel were measured and compared with those of age-matched control subjects (n = 31) by using principal component analysis and Wilcoxon rank sum tests with correction. Median age at transplantation was 1.3 years (range, 0.2-4.8 years), and median time of pre-HCT sample to transplantation was 0.1 year. Normal leukocyte enzyme activity levels were achieved in 93% of patients post-HCT. Pretransplant samples showed clear separation of patients and control subjects. Markers that differentiated pre-HCT between control subjects and patients were mainly pro-inflammatory (50%) or related to bone homeostasis and extracellular matrix degradation (33%). After 10 years’ follow-up, only 5 markers (receptor activator of nuclear factor kappa-Β ligand, osteoprotegerin, axis inhibition protein 1 [AXIN1], stem cell factor, and Fms-related tyrosine kinase 3 ligand) remained significantly increased, with a large fold change difference between patients with MPS I and control subjects. In conclusion, systemic inflammation is present in untreated MPS patients and is reduced upon treatment with HCT. Markers related to bone homeostasis remain elevated up to 10 years after HCT and possibly reflect the ongoing skeletal disease, making them potential biomarkers for the evaluation of new therapies.
- Published
- 2021
- Full Text
- View/download PDF
29. Model-Based Dosing of Anti-Thymocyte Globulin in Pediatric Allogeneic Hematopoietic Cell Transplantation Improves Survival Chances: Updated Results from the Single Arm Phase II Parachute-Trial Combined with Real-World Data
- Author
-
Admiraal, Rick, Nierkens, Stefan, Bierings, Marc, Belderbos, Mirjam, Huitema, Alwin D.R., Bredius, Robbert, Jiang, Yilin, Curran, Kevin J., Harris, Andrew C., Scaradavou, Andromachi, Cancio, Maria I., Klein, Elizabeth, Kollen, Wouter, Bresters, Dorine, Calkoen, Friso, Versluijs, A. Birgitta, Zwaan, Christian M., Boelens, Jaap-Jan, and Lindemans, Caroline A.
- Abstract
Anti-thymocyte globulin (ATG) is used in the conditioning for pediatric hematopoietic cell transplantation (HCT) to prevent graft-versus-host-disease (GvHD) and graft failure (GF). Toxicity includes poor T-cell recovery, associated with viral reactivations and higher mortality. The PARACHUTE-trial1(non-randomized prospective trial investigating model-based dosing [MBD] compared to historical fixed dose of ATG Thymoglobulin) showed that MBD of ATG improves T-cell recovery compared to fixed dosing, while maintaining an anti-GvHD effect. We now evaluated outcome after 5-year follow-up combined with real-world data.
- Published
- 2024
- Full Text
- View/download PDF
30. Viral PCR Positivity in Stool before Allogeneic Hematopoietic Cell Transplantation is Strongly Associated with Acute Intestinal Graft-versus-Host Disease
- Author
-
van Montfrans, Joris, Schulz, Laura, Versluys, Birgitta, de Wildt, Arianne, Wolfs, Tom, Bierings, Marc, Gerhardt, Corinne, Lindemans, Caroline, Wensing, Anne, and Boelens, Jaap Jan
- Abstract
Acute graft-versus-host disease (aGVHD) can be triggered by inflammatory conditions, including infections and mucositis. We investigated the association between PCR positivity for gastrointestinal (GI) viruses in stool before hematopoietic cell transplantation (HCT) and intestinal aGVHD using Cox proportional hazard models. We included 48 consecutive HCT patients (28 with malignancies and 20 with nonmalignancies) without GI symptoms before HCT. Fifteen patients were GI virus positive: 9 adenovirus, 3 norovirus, 2 parechovirus, and 1 astrovirus. Overall survival was 58% ± 8%. The cumulative incidence of aGVHD grade 2 to 4 was 43% ± 8% (n = 18) after a median of 47 days (range, 14 to 140). In univariate analysis, GI virus PCR positivity was the only predictor for aGVHD (P = .008): within the group of GI virus PCR-positive patients, the cumulative incidence of aGVHD 2 to 4 was 70% ± 12% versus 29 ± 8% in the PCR-negative group (P = .004). In conclusion, GI virus PCR positivity before HCT predicted development of intestinal aGVHD. These results may ultimately affect monitoring, aGVHD prophylaxis, and treatment, as well as rescheduling of elective HCTs.
- Published
- 2024
- Full Text
- View/download PDF
31. Association of busulfan exposure and outcomes after HCT for patients with an inborn error of immunity
- Author
-
Bognàr, Tim, Garcia-Rosa, Moises, Lalmohamed, Arief, Güngör, Tayfun, Hauri-Hohl, Mathias, Prockop, Susan, Oram, Layne, Pai, Sung-Yun, Brooks, Jordan, Savic, Rada M., Dvorak, Christopher C., Long-Boyle, Janel R., Krajinovic, Maja, Bittencourt, Henrique, Teyssier, Anne-Charlotte, Théorêt, Yves, Martinez, Cary, Egberts, Toine C. G., Morales, Erin, Slatter, Mary, Cuvelier, Geoffrey D. E., Chiesa, Robert, Wynn, Robert F., Coussons, Mary, Cicalese, Maria P., Ansari, Marc, Long, Susan E., Ebens, Christen L., Lust, Hannah, Chaudhury, Sonali, Nath, Christa E., Shaw, Peter J., Keogh, Steven J., van der Stoep, M. Y. Eileen C., Bredius, Robbert, Lindemans, Caroline A., Boelens, Jaap-Jan, and Bartelink, Imke H.
- Abstract
•In patients with IEI, improved EFS and higher donor chimerism may be achieved by targeting a cumulative busulfan AUC of 80 mg × h/L.•The data stress the importance of uniformly using a validated population pharmacokinetic model to estimate the busulfan cumulative exposure.
- Published
- 2024
- Full Text
- View/download PDF
32. The pulmonary metatranscriptome prior to pediatric HCT identifies post-HCT lung injury
- Author
-
Zinter, Matt S., Lindemans, Caroline A., Versluys, Birgitta A., Mayday, Madeline Y., Sunshine, Sara, Reyes, Gustavo, Sirota, Marina, Sapru, Anil, Matthay, Michael A., Kharbanda, Sandhya, Dvorak, Christopher C., Boelens, Jaap J., and DeRisi, Joseph L.
- Abstract
Lung injury after pediatric allogeneic hematopoietic cell transplantation (HCT) is a common and disastrous complication that threatens long-term survival. To develop strategies to prevent lung injury, novel tools are needed to comprehensively assess lung health in HCT candidates. Therefore, this study analyzed biospecimens from 181 pediatric HCT candidates who underwent routine pre-HCT bronchoalveolar lavage (BAL) at the University Medical Center Utrecht between 2005 and 2016. BAL fluid underwent metatranscriptomic sequencing of microbial and human RNA, and unsupervised clustering and generalized linear models were used to associate microbiome gene expression data with the development of post-HCT lung injury. Microbe-gene correlations were validated using a geographically distinct cohort of 18 pediatric HCT candidates. The cumulative incidence of post-HCT lung injury varied significantly according to 4 pre-HCT pulmonary metatranscriptome clusters, with the highest incidence observed in children with pre-HCT viral enrichment and innate immune activation, as well as in children with profound microbial depletion and concomitant natural killer/T-cell activation (P < .001). In contrast, children with pre-HCT pulmonary metatranscriptomes containing diverse oropharyngeal taxa and lacking inflammation rarely developed post-HCT lung injury. In addition, activation of epithelial-epidermal differentiation, mucus production, and cellular adhesion were associated with fatal post-HCT lung injury. In a separate validation cohort, associations among pulmonary respiratory viral load, oropharyngeal taxa, and pulmonary gene expression were recapitulated; the association with post-HCT lung injury needs to be validated in an independent cohort. This analysis suggests that assessment of the pre-HCT BAL fluid may identify high-risk pediatric HCT candidates who may benefit from pathobiology-targeted interventions.
- Published
- 2021
- Full Text
- View/download PDF
33. The pulmonary metatranscriptome prior to pediatric HCT identifies post-HCT lung injury
- Author
-
Zinter, Matt S., Lindemans, Caroline A., Versluys, Birgitta A., Mayday, Madeline Y., Sunshine, Sara, Reyes, Gustavo, Sirota, Marina, Sapru, Anil, Matthay, Michael A., Kharbanda, Sandhya, Dvorak, Christopher C., Boelens, Jaap J., and DeRisi, Joseph L.
- Abstract
Lung injury after pediatric allogeneic hematopoietic cell transplantation (HCT) is a common and disastrous complication that threatens long-term survival. To develop strategies to prevent lung injury, novel tools are needed to comprehensively assess lung health in HCT candidates. Therefore, this study analyzed biospecimens from 181 pediatric HCT candidates who underwent routine pre-HCT bronchoalveolar lavage (BAL) at the University Medical Center Utrecht between 2005 and 2016. BAL fluid underwent metatranscriptomic sequencing of microbial and human RNA, and unsupervised clustering and generalized linear models were used to associate microbiome gene expression data with the development of post-HCT lung injury. Microbe-gene correlations were validated using a geographically distinct cohort of 18 pediatric HCT candidates. The cumulative incidence of post-HCT lung injury varied significantly according to 4 pre-HCT pulmonary metatranscriptome clusters, with the highest incidence observed in children with pre-HCT viral enrichment and innate immune activation, as well as in children with profound microbial depletion and concomitant natural killer/T-cell activation (P< .001). In contrast, children with pre-HCT pulmonary metatranscriptomes containing diverse oropharyngeal taxa and lacking inflammation rarely developed post-HCT lung injury. In addition, activation of epithelial-epidermal differentiation, mucus production, and cellular adhesion were associated with fatal post-HCT lung injury. In a separate validation cohort, associations among pulmonary respiratory viral load, oropharyngeal taxa, and pulmonary gene expression were recapitulated; the association with post-HCT lung injury needs to be validated in an independent cohort. This analysis suggests that assessment of the pre-HCT BAL fluid may identify high-risk pediatric HCT candidates who may benefit from pathobiology-targeted interventions.
- Published
- 2021
- Full Text
- View/download PDF
34. CD4+ T-cell reconstitution predicts survival outcomes after acute graft-versus-host-disease: a dual-center validation
- Author
-
de Koning, Coco, Prockop, Susan, van Roessel, Ichelle, Kernan, Nancy, Klein, Elizabeth, Langenhorst, Jurgen, Szanto, Celina, Belderbos, Mirjam, Bierings, Marc, Boulad, Farid, Bresters, Dorine, Cancio, Maria, Curran, Kevin, Kollen, Wouter, O’Reilly, Richard, Scaradavou, Andromachi, Spitzer, Barbara, Versluijs, Birgitta, Huitema, Alwin, Lindemans, Caroline, Nierkens, Stefan, and Boelens, Jaap Jan
- Abstract
Acute graft-versus-host-Disease (aGVHD) is a major cause of morbidity and mortality after allogeneic hematopoietic cell transplantation (HCT). We previously showed that early CD4+ T-cell immune reconstitution (IR; CD4+ IR) predicts survival after HCT. Here, we studied the relation between CD4+ IR and survival in patients developing aGVHD. Pediatric patients undergoing first allogeneic HCT at University Medical Center Utrecht (UMC)/Princess Máxima Center (PMC) or Memorial Sloan Kettering Cancer Center (MSK) were included. Primary outcomes were nonrelapse mortality (NRM) and overall survival (OS), stratified for aGVHD and CD4+ IR, defined as ≥50 CD4+ T cells per μL within 100 days after HCT or before aGVHD onset. Multivariate and time-to-event Cox proportional hazards models were applied, and 591 patients (UMC/PMC, n = 276; MSK, n = 315) were included. NRM in patients with grade 3 to 4 aGVHD with or without CD4+ IR within 100 days after HCT was 30% vs 80% (P = .02) at UMC/PMC and 5% vs 67% (P = .02) at MSK. This was associated with lower OS without CD4+ IR (UMC/PMC, 61% vs 20%; P = .04; MSK, 75% vs 33%; P = .12). Inadequate CD4+ IR before aGVHD onset was associated with significantly higher NRM (74% vs 12%; P < .001) and inferior OS (24% vs 78%; P < .001). In this retrospective analysis, we demonstrate that early CD4+ IR, a simple and robust marker predictive of outcomes after HCT, is associated with survival after moderate to severe aGVHD. This association must be confirmed prospectively but suggests strategies to improve T-cell recovery after HCT may influence survival in patients developing aGVHD.
- Published
- 2021
- Full Text
- View/download PDF
35. CD4+T-cell reconstitution predicts survival outcomes after acute graft-versus-host-disease: a dual-center validation
- Author
-
de Koning, Coco, Prockop, Susan, van Roessel, Ichelle, Kernan, Nancy, Klein, Elizabeth, Langenhorst, Jurgen, Szanto, Celina, Belderbos, Mirjam, Bierings, Marc, Boulad, Farid, Bresters, Dorine, Cancio, Maria, Curran, Kevin, Kollen, Wouter, O'Reilly, Richard, Scaradavou, Andromachi, Spitzer, Barbara, Versluijs, Birgitta, Huitema, Alwin, Lindemans, Caroline, Nierkens, Stefan, and Boelens, Jaap Jan
- Abstract
Acute graft-versus-host-Disease (aGVHD) is a major cause of morbidity and mortality after allogeneic hematopoietic cell transplantation (HCT). We previously showed that early CD4+T-cell immune reconstitution (IR; CD4+IR) predicts survival after HCT. Here, we studied the relation between CD4+IR and survival in patients developing aGVHD. Pediatric patients undergoing first allogeneic HCT at University Medical Center Utrecht (UMC)/Princess Máxima Center (PMC) or Memorial Sloan Kettering Cancer Center (MSK) were included. Primary outcomes were nonrelapse mortality (NRM) and overall survival (OS), stratified for aGVHD and CD4+IR, defined as ≥50 CD4+T cells per μL within 100 days after HCT or before aGVHD onset. Multivariate and time-to-event Cox proportional hazards models were applied, and 591 patients (UMC/PMC, n = 276; MSK, n = 315) were included. NRM in patients with grade 3 to 4 aGVHD with or without CD4+IR within 100 days after HCT was 30% vs 80% (P= .02) at UMC/PMC and 5% vs 67% (P= .02) at MSK. This was associated with lower OS without CD4+IR (UMC/PMC, 61% vs 20%; P= .04; MSK, 75% vs 33%; P= .12). Inadequate CD4+IR before aGVHD onset was associated with significantly higher NRM (74% vs 12%; P< .001) and inferior OS (24% vs 78%; P< .001). In this retrospective analysis, we demonstrate that early CD4+IR, a simple and robust marker predictive of outcomes after HCT, is associated with survival after moderate to severe aGVHD. This association must be confirmed prospectively but suggests strategies to improve T-cell recovery after HCT may influence survival in patients developing aGVHD.
- Published
- 2021
- Full Text
- View/download PDF
36. Comparison of Outcomes in Patients with Cerebral Adrenoleukodystrophy (CALD) Receiving Elivaldogene Autotemcel (eli-cel; Lenti-D) Gene Therapy in Clinical Trials Versus Those Receiving Allogeneic Hematopoietic Stem Cell Transplant in a Contemporaneous Comparator Study
- Author
-
Duncan, Christine N., Kühl, Jörn-Sven, Chiesa, Robert, Boelens, Jaap-Jan, Eichler, Florian, Sevin, Caroline, Dalle, Jean-Hugues, De Oliveira, Satiro N., Amartino, Hernan M., Kapoor, Neena, Prasad, Vinod K., Jones, Simon, Algeri, Mattia, Bunin, Nancy J., Diaz-de-Heredia, Cristina, Thrasher, Adrian J., Fernandes, Juliana Folloni, Smith, Nicholas, Shah, Ami J, Locatelli, Franco, Engelen, Marc, Lindemans, Caroline A., Dietz, Andrew C., Pan, Lin, Sieker, Jakob, Williams, David A., and Orchard, Paul J.
- Published
- 2022
- Full Text
- View/download PDF
37. Efficacy of MSC for steroid-refractory acute GVHD associates with MSC donor age and a defined molecular profile
- Author
-
van der Wagen, Lotte E., Miranda-Bedate, Alberto, Janssen, Anke, Fernando, Febilla, Appukudige, Nagesha, van Dooremalen, Sanne, Westinga, Kasper, Admiraal, Rick, Lorenowicz, Magdalena J., Huls, Gerwin, Janssen, Jeroen J. W. M., Broers, Annoek E. C., van der Velden, Walter J. F. M., van Marwijk Kooy, Rien, Hazenberg, Mette D., de Haar, Colin, Lindemans, Caroline, Jan Boelens, Jaap, and Kuball, Jürgen
- Published
- 2020
- Full Text
- View/download PDF
38. Hematopoietic cell transplantation in chronic granulomatous disease: a study of 712 children and adults
- Author
-
Chiesa, Robert, Wang, Junfeng, Blok, Henric-Jan, Hazelaar, Sheree, Neven, Benedicte, Moshous, Despina, Schulz, Ansgar, Hoenig, Manfred, Hauck, Fabian, Al Seraihy, Amal, Gozdzik, Jolanta, Ljungman, Per, Lindemans, Caroline A., Fernandes, Juliana F., Kalwak, Krzysztof, Strahm, Brigitte, Schanz, Urs, Sedlacek, Petr, Sykora, Karl-Walter, Aksoylar, Serap, Locatelli, Franco, Stepensky, Polina, Wynn, Robert, Lum, Su Han, Zecca, Marco, Porta, Fulvio, Taskinen, Mervi, Gibson, Brenda, Matthes, Susanne, Karakukcu, Musa, Hauri-Hohl, Mathias, Veys, Paul, Gennery, Andrew R., Lucchini, Giovanna, Felber, Matthias, Albert, Michael H., Balashov, Dmitry, Lankester, Arjan, Güngör, Tayfun, and Slatter, Mary A.
- Abstract
Chronic granulomatous disease (CGD) is a primary immunodeficiency resulting in life-threatening infections and inflammatory complications. Allogeneic hematopoietic cell transplantation (allo-HCT) can cure the disease, but the indication to transplant remains controversial. We performed a retrospective multicenter study of 712 patients with CGD who underwent allo-HCT transplantation from March 1993 through December 2018. We studied 635 children (aged <18 years) and 77 adults. Median follow-up was 45 months. Median age at transplantation was 7 years (range, 0.1-48.6). Kaplan-Meier estimates of overall survival (OS) and event-free survival (EFS) at 3 years were 85.7% and 75.8%, respectively. In multivariate analysis, older age was associated with reduced survival and increased chronic graft-versus-host disease. Nevertheless, OS and EFS at 3 years for patients ≥18 years were 76% and 69%, respectively. Use of 1-antigen-mismatched donors was associated with reduced OS and EFS . No significant difference was found in OS, but a significantly reduced EFS was noted in the small group of patients who received a transplant from a donor with a >1 antigen mismatch. Choice of conditioning regimen did not influence OS or EFS. In summary, we report an excellent outcome after allo-HCT in CGD, with low incidence of graft failure and mortality in all ages. Older patients and recipients of 1-antigen-mismatched grafts had a less favorable outcome. Transplantation should be strongly considered at a younger age and particularly in the presence of a well-matched donor.
- Published
- 2020
- Full Text
- View/download PDF
39. Hematopoietic cell transplantation in chronic granulomatous disease: a study of 712 children and adults
- Author
-
Chiesa, Robert, Wang, Junfeng, Blok, Henric-Jan, Hazelaar, Sheree, Neven, Benedicte, Moshous, Despina, Schulz, Ansgar, Hoenig, Manfred, Hauck, Fabian, Al Seraihy, Amal, Gozdzik, Jolanta, Ljungman, Per, Lindemans, Caroline A., Fernandes, Juliana F., Kalwak, Krzysztof, Strahm, Brigitte, Schanz, Urs, Sedlacek, Petr, Sykora, Karl-Walter, Aksoylar, Serap, Locatelli, Franco, Stepensky, Polina, Wynn, Robert, Lum, Su Han, Zecca, Marco, Porta, Fulvio, Taskinen, Mervi, Gibson, Brenda, Matthes, Susanne, Karakukcu, Musa, Hauri-Hohl, Mathias, Veys, Paul, Gennery, Andrew R., Lucchini, Giovanna, Felber, Matthias, Albert, Michael H., Balashov, Dmitry, Lankester, Arjan, Güngör, Tayfun, and Slatter, Mary A.
- Abstract
Chronic granulomatous disease (CGD) is a primary immunodeficiency resulting in life-threatening infections and inflammatory complications. Allogeneic hematopoietic cell transplantation (allo-HCT) can cure the disease, but the indication to transplant remains controversial. We performed a retrospective multicenter study of 712 patients with CGD who underwent allo-HCT transplantation from March 1993 through December 2018. We studied 635 children (aged <18 years) and 77 adults. Median follow-up was 45 months. Median age at transplantation was 7 years (range, 0.1-48.6). Kaplan-Meier estimates of overall survival (OS) and event-free survival (EFS) at 3 years were 85.7% and 75.8%, respectively. In multivariate analysis, older age was associated with reduced survival and increased chronic graft-versus-host disease. Nevertheless, OS and EFS at 3 years for patients ≥18 years were 76% and 69%, respectively. Use of 1-antigen-mismatched donors was associated with reduced OS and EFS . No significant difference was found in OS, but a significantly reduced EFS was noted in the small group of patients who received a transplant from a donor with a >1 antigen mismatch. Choice of conditioning regimen did not influence OS or EFS. In summary, we report an excellent outcome after allo-HCT in CGD, with low incidence of graft failure and mortality in all ages. Older patients and recipients of 1-antigen-mismatched grafts had a less favorable outcome. Transplantation should be strongly considered at a younger age and particularly in the presence of a well-matched donor.
- Published
- 2020
- Full Text
- View/download PDF
40. Hurdles in treating Hurler disease: potential routes to achieve a “real” cure
- Author
-
van den Broek, Brigitte T. A., van Doorn, Jaap, Hegeman, Charlotte V., Nierkens, Stefan, Lindemans, Caroline A., Verhoeven-Duif, Nanda, Boelens, Jaap Jan, and van Hasselt, Peter M.
- Abstract
Mucopolysaccharidoses (MPSs) are multiorgan devastating diseases for which hematopoietic cell transplantation (HCT) and, to a lesser extent, enzyme replacement therapy have substantially altered the course of the disease. Furthermore, they have resulted in increased overall survival, especially for Hurler disease (MPS-1). However, despite the identification of clinical predictors and harmonized transplantation protocols, disease progression still poses a significant burden to patients, although at a slower pace. To design better therapies, we need to understand why and where current therapies fail. In this review, we discuss important aspects of the underlying disease and the disease progression. We note that the majority of progressive symptoms that occur in “hard-to-treat” tissues are actually tissues that are difficult to reach, such as avascular connective tissue or tissues isolated from the circulation by a specific barrier (eg, blood-brain barrier, blood-retina barrier). Although easily reached tissues are effectively cured by HCT, disease progression is observed in these “hard-to-reach” tissues. We used these insights to critically appraise ongoing experimental endeavors with regard to their potential to overcome the encountered hurdles and improve long-term clinical outcomes in MPS patients treated with HCT.
- Published
- 2020
- Full Text
- View/download PDF
41. Hurdles in treating Hurler disease: potential routes to achieve a “real” cure
- Author
-
van den Broek, Brigitte T.A., van Doorn, Jaap, Hegeman, Charlotte V., Nierkens, Stefan, Lindemans, Caroline A., Verhoeven-Duif, Nanda, Boelens, Jaap Jan, and van Hasselt, Peter M.
- Abstract
Mucopolysaccharidoses (MPSs) are multiorgan devastating diseases for which hematopoietic cell transplantation (HCT) and, to a lesser extent, enzyme replacement therapy have substantially altered the course of the disease. Furthermore, they have resulted in increased overall survival, especially for Hurler disease (MPS-1). However, despite the identification of clinical predictors and harmonized transplantation protocols, disease progression still poses a significant burden to patients, although at a slower pace. To design better therapies, we need to understand why and where current therapies fail. In this review, we discuss important aspects of the underlying disease and the disease progression. We note that the majority of progressive symptoms that occur in “hard-to-treat” tissues are actually tissues that are difficult to reach, such as avascular connective tissue or tissues isolated from the circulation by a specific barrier (eg, blood-brain barrier, blood-retina barrier). Although easily reached tissues are effectively cured by HCT, disease progression is observed in these “hard-to-reach” tissues. We used these insights to critically appraise ongoing experimental endeavors with regard to their potential to overcome the encountered hurdles and improve long-term clinical outcomes in MPS patients treated with HCT.
- Published
- 2020
- Full Text
- View/download PDF
42. Longitudinal Blood Count Analysis Reveals That Poor Graft Function after Pediatric Hematopoietic Cell Transplantation Is a Common Complication Associated with Poor Outcome
- Author
-
Müskens, Konradin F., Collot-d'Escury, Winny N.R., Dandis, Rana, Haitjema, Saskia, Lindemans, Caroline A., Nierkens, Stefan, and Belderbos, Mirjam E.
- Abstract
Background
- Published
- 2023
- Full Text
- View/download PDF
43. High Risk of GvHD in Children Transplanted for Refractory Cytopenia of Childhood: Importance of Sufficient Exposure to Anti-Thymocyte Globulin
- Author
-
Koopman-Coenen, Eva, Meesters-Ensing, Joyce, Nierkens, Stefan, Kal, Ireen J., Müskens, Konradin F., Versluijs, Birgitta, Lindemans, Caroline A., Harris, Andrew C., Bierings, Marc, Admiraal, Rick, and Belderbos, Mirjam E.
- Abstract
Introduction
- Published
- 2023
- Full Text
- View/download PDF
44. IL-33 Induces Paneth Cell Production of EGF and Soluble ST2, Regulating Epithelial Regeneration after Intestinal Injury
- Author
-
Calafiore, Marco, Fu, YA-Yuan, Vinci, Paola, Arnhold, Viktor, Chang, Winston, Jansen, Suze, Egorova, Anastasiya, Takashima, Shuichiro, Kuttiyara, Jason, Ito, Takahiro, Serody, Jonathan, Nakae, Susumu, Turnquist, Heth, van Es, Johan, Clevers, Hans, Lindemans, Caroline A., Blazar, Bruce R, and Hanash, Alan M.
- Abstract
Crypt base intestinal stem cells (ISCs) maintain the epithelial lining of the intestines, but their frequencies are reduced in experimental models of graft vs. host disease (GVHD). Paneth cells provide an epithelial contribution to the stem cell niche, but their frequencies are also reduced in GVHD mouse models and in patients with GVHD. Mechanisms regulating ISCs and their niche after damage remain poorly understood. Interleukin-33 (IL-33) is an immunomodulatory alarmin typically thought to target lymphocytes such as T cells and innate lymphoid cells. In experimental models of allogeneic bone marrow transplantation, IL-33 can promote or attenuate GVHD, depending on the cellular target and the timing of the exposure. A secreted isoform of the IL-33 receptor, termed soluble ST2 (sST2), acts as a negative regulator by blocking IL-33 from binding to the membrane-bound isoform that mediates intracellular signaling. sST2 also has diagnostic and prognostic utility, serving as a biomarker for GVHD severity. While IL-33 has well-described effects on lymphocytes populations, there is limited understanding of the role of IL-33 signaling within the intestinal mucosa after damage.
- Published
- 2023
- Full Text
- View/download PDF
45. Clonal Hematopoiesis Is Common in Long-Term Survivors of Pediatric Hematopoietic Cell Transplantation, Including Umbilical Cord Blood Transplantation
- Author
-
Müskens, Konradin F., van Bergen, Maaike G.J.M., de Graaf, Aniek O., Wieringa, Nienke, te Pas, Brigit M., Pagter, Anne P.J. de, Bense, Joëll E., Lankester, Arjan C., Kremer, Leontien C.M., Jansen, Joop H., Huls, Geert A., Nierkens, Stefan, Lindemans, Caroline A., and Belderbos, Mirjam E.
- Abstract
Background
- Published
- 2023
- Full Text
- View/download PDF
46. Early Lymphocyte Immune Reconstitution As Predictor for Outcomes after Allogeneic Hematopoietic Cell Transplantation for Malignant Indications; A Tri-Institutional Analysis
- Author
-
Troullioud Lucas, Alexandre G., Lindemans, Caroline A., Bhoopalan, Senthil Velan, Dandis, Rana, Prockop, Susan, Keerthi, Dinesh, de Koning, Coco, Sharma, Akshay, Nierkens, Stefan, and Boelens, Jaap-Jan
- Published
- 2023
- Full Text
- View/download PDF
47. Increased overall and bacterial infections following myeloablative allogeneic HCT for patients with AML in CR1
- Author
-
Ustun, Celalettin, Kim, Soyoung, Chen, Min, Beitinjaneh, Amer M., Brown, Valerie I., Dahi, Parastoo B., Daly, Andrew, Diaz, Miguel Angel, Freytes, Cesar O., Ganguly, Siddhartha, Hashmi, Shahrukh, Hildebrandt, Gerhard C., Lazarus, Hillard M., Nishihori, Taiga, Olsson, Richard F., Page, Kristin M., Papanicolaou, Genovefa, Saad, Ayman, Seo, Sachiko, William, Basem M., Wingard, John R., Wirk, Baldeep, Yared, Jean A., Perales, Miguel-Angel, Auletta, Jeffery J., Komanduri, Krishna V., Lindemans, Caroline A., and Riches, Marcie L.
- Abstract
Presumably, reduced-intensity/nonmyeloablative conditioning (RIC/NMA) for allogeneic hematopoietic cell transplantation (alloHCT) results in reduced infections compared with myeloablative conditioning (MAC) regimens; however, published evidence is limited. In this Center for International Blood and Marrow Transplant Research study, 1755 patients (aged ≥40 years) with acute myeloid leukemia in first complete remission were evaluated for infections occurring within 100 days after T-cell replete alloHCT. Patients receiving RIC/NMA (n = 777) compared with those receiving MAC (n = 978) were older and underwent transplantation more recently; however, the groups were similar regarding Karnofsky performance score, HCT–comorbidity index, and cytogenetic risk. One or more infections occurred in 1045 (59.5%) patients (MAC, 595 [61%]; RIC/NMA, 450 [58%]; P= .21) by day 100. The median time to initial infection after MAC conditioning occurred earlier (MAC, 15 days [range, <1-99 days]; RIC/NMA, 21 days [range, <1-100 days]; P< .001). Patients receiving MAC were more likely to experience at least 1 bacterial infection by day 100 (MAC, 46% [95% confidence interval (CI), 43-49]; RIC/NMA, 37% [95% CI, 34-41]; P= .0004), whereas at least a single viral infection was more prevalent in the RIC/NMA cohort (MAC, 34% [95% CI, 31-37]; RIC/NMA, 39% [95% CI, 36-42]; P= .046). MAC remained a risk factor for bacterial infections in multivariable analysis (relative risk, 1.44; 95% CI, 1.23-1.67; P< .0001). Moreover, the rate of any infection per patient-days at risk in the first 100 days (infection density) after alloHCT was greater for the MAC cohort (1.21; 95% CI, 1.11-1.32; P< .0001). RIC/NMA was associated with reduced infections, especially bacterial infections, in the first 100 days after alloHCT.
- Published
- 2019
- Full Text
- View/download PDF
48. Increased overall and bacterial infections following myeloablative allogeneic HCT for patients with AML in CR1
- Author
-
Ustun, Celalettin, Kim, Soyoung, Chen, Min, Beitinjaneh, Amer M., Brown, Valerie I., Dahi, Parastoo B., Daly, Andrew, Diaz, Miguel Angel, Freytes, Cesar O., Ganguly, Siddhartha, Hashmi, Shahrukh, Hildebrandt, Gerhard C., Lazarus, Hillard M., Nishihori, Taiga, Olsson, Richard F., Page, Kristin M., Papanicolaou, Genovefa, Saad, Ayman, Seo, Sachiko, William, Basem M., Wingard, John R., Wirk, Baldeep, Yared, Jean A., Perales, Miguel-Angel, Auletta, Jeffery J., Komanduri, Krishna V., Lindemans, Caroline A., and Riches, Marcie L.
- Abstract
Presumably, reduced-intensity/nonmyeloablative conditioning (RIC/NMA) for allogeneic hematopoietic cell transplantation (alloHCT) results in reduced infections compared with myeloablative conditioning (MAC) regimens; however, published evidence is limited. In this Center for International Blood and Marrow Transplant Research study, 1755 patients (aged ≥40 years) with acute myeloid leukemia in first complete remission were evaluated for infections occurring within 100 days after T-cell replete alloHCT. Patients receiving RIC/NMA (n = 777) compared with those receiving MAC (n = 978) were older and underwent transplantation more recently; however, the groups were similar regarding Karnofsky performance score, HCT–comorbidity index, and cytogenetic risk. One or more infections occurred in 1045 (59.5%) patients (MAC, 595 [61%]; RIC/NMA, 450 [58%]; P = .21) by day 100. The median time to initial infection after MAC conditioning occurred earlier (MAC, 15 days [range, <1-99 days]; RIC/NMA, 21 days [range, <1-100 days]; P < .001). Patients receiving MAC were more likely to experience at least 1 bacterial infection by day 100 (MAC, 46% [95% confidence interval (CI), 43-49]; RIC/NMA, 37% [95% CI, 34-41]; P = .0004), whereas at least a single viral infection was more prevalent in the RIC/NMA cohort (MAC, 34% [95% CI, 31-37]; RIC/NMA, 39% [95% CI, 36-42]; P = .046). MAC remained a risk factor for bacterial infections in multivariable analysis (relative risk, 1.44; 95% CI, 1.23-1.67; P < .0001). Moreover, the rate of any infection per patient-days at risk in the first 100 days (infection density) after alloHCT was greater for the MAC cohort (1.21; 95% CI, 1.11-1.32; P < .0001). RIC/NMA was associated with reduced infections, especially bacterial infections, in the first 100 days after alloHCT.
- Published
- 2019
- Full Text
- View/download PDF
49. Virus detection in the cerebrospinal fluid of hematopoietic stem cell transplant recipients is associated with poor patient outcomes: a CIBMTR contemporary longitudinal study
- Author
-
Abidi, Maheen Z., Hari, Parameswaran, Chen, Min, Kim, Soyoung, Battiwala, Minoo, Dahi, Parastoo Bahrami, Diaz, Miguel Angel, Gale, Robert Peter, Ganguly, Siddhartha, Gergis, Usama, Green, Jaime, Hildebrandt, Gerhard, Hill, Joshua A., Komanduri, Krishna, Lazarus, Hillard, Marks, David, Nishihori, Taiga, Olsson, Richard, Seo, Sachiko, Ustun, Celalettin, Yared, Jean, Yin, Dwight, Wingard, John, Wirk, Baldeep Mona, Auletta, Jeffrey, Lindemans, Caroline, and Riches, Marcie
- Abstract
Limited data exist on characteristics of central nervous system viruses (CNS-V) in allogeneic hematopoietic stem cell transplant (HCT) recipients. Between 2007 and 2015, the Center for International Blood and Marrow Transplant Research (CIBMTR) received information on 27,532 patients undergoing HCT. Of these, centers reported 165 HCT recipients with CNS-V detected in cerebrospinal fluid within 6 months after HCT. CNS viruses predominantly included human herpes virus 6 (HHV-6) (73%), followed by Epstein-Barr Virus (10%), cytomegalovirus (3%), varicella zoster virus (3%), herpes simplex virus (3%) and Adenovirus (3%). Median time of viral detection in CNS was 31 days after HCT; and viral detection was earlier in patients with CNS HHV-6. Concurrent viremia occurred in 52% of patients. Cord blood transplant recipients (CBT) accounted for the majority (53%) of patients with CNS-V. Myeloablative conditioning (65%), use of fludarabine (63%), or use of anti-thymocyte globulin (61%) were also predominant. Overall survival from the time of detection of CNS-V was 50% at 6 months and 30% at 5 years. Infections were the leading cause of death (32%). In summary, CBT recipients predominated in the population with CNS-V. Outcomes after CNS-V were poor with significant mortality seen in the first 6 months.
- Published
- 2019
- Full Text
- View/download PDF
50. Bacterial blood stream infections (BSIs), particularly post-engraftment BSIs, are associated with increased mortality after allogeneic hematopoietic cell transplantation
- Author
-
Ustun, Celalettin, Young, Jo-Anne H., Papanicolaou, Genovefa A., Kim, Soyoung, Ahn, Kwang Woo, Chen, Min, Abdel-Azim, Hisham, Aljurf, Mahmoud, Beitinjaneh, Amer, Brown, Valerie, Cerny, Jan, Chhabra, Saurabh, Kharfan-Dabaja, Mohamed A., Dahi, Parastoo B., Daly, Andrew, Dandoy, Christopher E., Dvorak, Christopher C., Freytes, Cesar O., Hashmi, Shahrukh, Lazarus, Hillard, Ljungman, Per, Nishihori, Taiga, Page, Kristin, Pingali, Sai R. K., Saad, Ayman, Savani, Bipin N., Weisdorf, Daniel, Williams, Kirsten, Wirk, Baldeep, Auletta, Jeffery J., Lindemans, Caroline A., Komanduri, Krishna, and Riches, Marcie
- Abstract
We analyzed CIBMTR data to evaluate the incidence of non-relapse mortality (NRM) and association with overall survival (OS) for bacterial blood stream infections (BSIs) occurring within 100 days of alloHCT in 2 different phases: pre-/peri-engraftment (BSI very early phase, BSI-VEP) and BSI post-engraftment (BSI occurring between 2 weeks after engraftment and day 100, late early phase, BSI-LEP). Of the 7128 alloHCT patients, 2656 (37%) had ≥1 BSI by day 100. BSI-VEP, BSI-LEP, and BSI-Both constituted 56% (n= 1492), 31% (n= 824), and 13% (n= 340) of total BSI, respectively. Starting in 2009, we observed a gradual decline in BSI incidence through 2012 (61–48%). Patients with BSI-VEP were more likely to receive a myeloablative conditioning (MAC) regimen with total body irradiation (TBI). NRM was significantly higher in patients with any BSI (RR 1.82 95% CI 1.63–2.04 for BSI-VEP, RR 2.46, 95% CI 2.05–2.96 for BSI-LEP, and RR 2.29, 95% CI 1.87–2.81 for BSI-Both) compared with those without BSI. OS was significantly lower in patients with any BSI compared with patients without BSI (RR 1.36, 95% CI 1.26–1.47 for BSI-VEP; RR 1.83, 95% CI 1.58–2.12 for BSI-LEP: RR 1.66, 95% CI 1.43–1.94 for BSI-Both). BSIs within day 100 after alloHCT are common and remain a risk factor for mortality.
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.